

**MEDEXUS PHARMACEUTICALS INC.**  
**10 King Street East, Suite 600**  
**Toronto, Ontario**  
**M5C 1C3**

September 11, 2023

**VIA SEDAR+**

Ontario Securities Commission, as Principal Regulator

Dear Sirs/Mesdames:

**RE: Medexus Pharmaceuticals Inc.**  
**Re: Preliminary Short Form Prospectus**  
**re: Qualification Certificate**

---

In connection with the filing of a preliminary short form prospectus of Medexus Pharmaceuticals Inc. (the “**Filer**”) dated September 11, 2023, and in accordance with clause 4.1(1)(a)(ii) of National Instrument 44-101 – *Short Form Prospectus Distributions* (“**NI 44-101**”), the Filer hereby:

- (A) advises that it is qualified to file a prospectus in the form of a short form prospectus pursuant to Section 2.2 of NI 44-101; and
- (B) certifies that:
  - (I) all of the qualification criteria in Section 2.2 of NI 44-101 have been satisfied; and
  - (II) all of the material incorporated by reference in the preliminary short form base shelf prospectus and not previously filed is being filed with the preliminary short form base shelf prospectus.

*[Remainder of page intentionally left blank]*

Yours truly,

**MEDEXUS PHARMACEUTICALS INC.**

By: (signed) “Ken d’Entremont”  
Name: Ken d'Entremont  
Title: Chief Executive Officer